A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications

NCT07189949 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors Harboring RAS Mutations or Amplifications

Interventions

DRUG: HRS-2329 Tablet

Sponsor

Jiangsu HengRui Medicine Co., Ltd.